Pharmaxis enrols first patient in its bone marrow cancer trial
Release Date: 23/02/2021 10:36am
Pharmaxis Ltd CEO Gary Phillips discusses with Proactive's Andrew Scott the news they've enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis. The trial aims to demonstrate that PXS‐5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients, who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Watch the interview here.
Categories: Video Content